ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK
hVIVO plc – Unaudited Interim Results for Six Months Ended 30 June 2025
Interim results Trading in line with expectations for full year Returning to growth in 2026
hVIVO plc (AIM: HVO) Appointment of Non-Executive Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that, further to its announcement on 29 July 2025, Shaun
hVIVO plc (AIM: HVO) Proposed appointment of Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation and the world leader in human challenge clinical trials, announces the appointment of Shaun Chilton as Non-Executive Chair, subject to successful completion of
hVIVO PLC (AIM:HVO) Notice of Trading Update
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the six months ended 30
Poolbeg Pharma: New Capital, New Catalysts as POLB 001 Advances in the Clinic
Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed £4.865 million equity raise and a series of high-impact developments across
hVIVO PLC (AIM:HVO) Positive results from client Phase 2b field study
Positive topline results from client Phase 2b field study
Poolbeg Pharma: New Capital, New Catalysts as POLB 001 Advances Toward the Clinic
Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed £4.7 million equity raise and a series of high-impact developments across
Poolbeg Pharma PLC (AIM:POLB) Director/PDMR Shareholding
Director Dealing
As AIM marks its 30th anniversary this week, I’ve been reflecting on the five IPOs I’ve led
As AIM turns 30 this week I’ve been reflecting on the 5 IPOs I’ve done on the market since 2012.
hVIVO PLC (AIM:HVO) Director/PDMR Shareholding
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin ‘Mo’ Khan, Chief
hVIVO PLC (AIM:HVO) Trading update
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it has received notification of a significant human challenge